High Risk Medicine Initiative

The aim of this initiative is to bring into focus high risk medicines and formalise how the pharmaceutical care is delivered to patients on these medications. Guidance and risk assessments for specific therapies (e.g. Lithium, Methotrexate) will be available from within the PCR.

These simple tools could be used to aid delivery of CMS to this high risk group of patients. The focus allows outcomes to be recorded and evidence gathered around specific areas which will help give clear benefits to patients and show benefits of the service to other stakeholders. This should demonstrate that by improving patient safety, pharmacists can contribute in a positive manner to the SG Quality Strategy around being patient-centred, safe and effective.